Improving prostate cancer treatment with targeted radiation therapy
MELT: Modulation of PSMA Expression for Lutetium Therapy
This study is looking at ways to make radiation therapy for prostate cancer work better by boosting a protein called PSMA on cancer cells, so if you're a patient with prostate cancer, this research could lead to improved treatment options for you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-10661630 on NIH RePORTER |
What this research studies
This research focuses on enhancing the effectiveness of a targeted radiation therapy for prostate cancer by increasing the expression of a specific protein called PSMA on cancer cells. The approach involves understanding how PSMA expression is regulated and testing treatments that can boost this expression or increase the sensitivity of tumors to radiation. By doing so, the researchers aim to improve patient responses to this therapy, which has already shown promise in previous studies. Ultimately, this work will help design a clinical trial to evaluate the combined effects of PSMA-targeted therapy and additional treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with castrate-resistant prostate cancer who have not responded adequately to existing therapies.
Not a fit: Patients with early-stage prostate cancer or those who have not yet developed castrate resistance may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with castrate-resistant prostate cancer.
How similar studies have performed: Previous studies have shown promising results with PSMA-targeted therapies, indicating that this approach has potential for success.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Hope, Thomas — University of California, San Francisco
- Study coordinator: Hope, Thomas
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.